Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash from Investing Activities: 2018-2025

Historic Cash from Investing Activities for Whitehawk Therapeutics (WHWK) over the last 6 years, with Sep 2025 value amounting to -$91.6 million.

  • Whitehawk Therapeutics' Cash from Investing Activities fell 1901.91% to -$91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year decrease of 47.97%. This contributed to the annual value of $25.2 million for FY2024, which is 69.71% down from last year.
  • Per Whitehawk Therapeutics' latest filing, its Cash from Investing Activities stood at -$91.6 million for Q3 2025, which was down 217.86% from -$28.8 million recorded in Q2 2025.
  • Whitehawk Therapeutics' Cash from Investing Activities' 5-year high stood at $115.5 million during Q1 2025, with a 5-year trough of -$91.6 million in Q3 2025.
  • In the last 3 years, Whitehawk Therapeutics' Cash from Investing Activities had a median value of $10.6 million in 2024 and averaged $9.4 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Cash from Investing Activities spiked by 371,507.65% in 2021, and later plummeted by 183,332.61% in 2022.
  • Quarterly analysis of 5 years shows Whitehawk Therapeutics' Cash from Investing Activities stood at -$46,000 in 2021, then plummeted by 183,332.61% to -$84.4 million in 2022, then skyrocketed by 104.32% to $3.6 million in 2023, then spiked by 259.91% to $13.1 million in 2024, then slumped by 1,901.91% to -$91.6 million in 2025.
  • Its Cash from Investing Activities stands at -$91.6 million for Q3 2025, versus -$28.8 million for Q2 2025 and $115.5 million for Q1 2025.